as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,212.1
Change
+9.9 (0.82%)
Open
₹1,208.2
Prev. Close
₹1,202.2
Day High
₹1,238.7
Day Low
₹1,112.4
Volume Analysis
Traded
957,390
Delivered
99,221
Delivery %
10.36%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (25.2%)
- •Strong operating margin (35.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (27.3%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,389.36 | ₹1,314.03 | ₹1,263.06 | ₹1,187.73 | ₹1,136.76 | ₹1,061.43 | ₹1,010.46 |
| Fibonacci | ₹1,314.03 | ₹1,265.78 | ₹1,235.98 | ₹1,187.73 | ₹1,139.48 | ₹1,109.68 | ₹1,061.43 |
| Camarilla | ₹1,246.83 | ₹1,235.26 | ₹1,223.68 | ₹1,187.73 | ₹1,200.52 | ₹1,188.95 | ₹1,177.37 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+102.51%
1 Week
+0.55%
1 Month
+24.75%
3 Months
+9.02%
6 Months
+80.01%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹170.91
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
17.76%
Net margin 26.62% × asset turnover 0.48x × equity multiplier 1.39x
Company Overview
Sector
Healthcare
Market Cap
₹13,545 Cr
P/E (TTM)
71.9
ROE
25.2%
Book Value
₹84.8
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Sudeep Pharma Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (25.2%); strong operating margin (35.0%). Strong 3-year EPS growth (27.3%).
TopFund Score — Fundamentals Quality
65/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 39.0% CAGR over last 5 years
- +Company has a good return on equity (ROE) track record: 3 Years ROE 31.8%
- −Stock is trading at 14.2 times its book value
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Submission of Transcript for the Earnings call held on 29.10.2026
Audio recording of the 29 October 2026 earnings call uploaded.
Submission of Newspaper Advertisement for unaudited Financials for the Quarter and Half Year ended 30th September 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 | 197 |
| Expenses + | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 | 123 |
| Operating Profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 | 73 |
| OPM % | 43.0% | 34.0% | 37.0% | 35.0% | 34.0% | 35.0% | 34.0% | 35.0% | 37.0% |
| Other Income + | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 | 6 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 3 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 |
| Profit before tax | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 | 71 |
| Tax % | 21.0% | 24.0% | 24.0% | 29.0% | 21.0% | 23.0% | 23.0% | 25.0% | 27.0% |
| Net Profit + | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 | 52 |
| EPS in Rs | 6 | 3 | 5 | 3 | 5 | 4 | 4 | 4 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 9 | 49 | 16 | 27 | 21 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 123 | 215 | 343 | 429 | 459 | 502 | 642 | 710 |
| Expenses + | 98 | 171 | 276 | 338 | 276 | 310 | 419 | 459 |
| Operating Profit | 25 | 44 | 67 | 90 | 183 | 192 | 223 | 251 |
| OPM % | 21.0% | 20.0% | 20.0% | 21.0% | 40.0% | 38.0% | 35.0% | 35.0% |
| Other Income + | 3 | 3 | 7 | 9 | 6 | 9 | 28 | 25 |
| Interest | 1 | 1 | 2 | 6 | 5 | 7 | 8 | 8 |
| Depreciation | 3 | 4 | 5 | 8 | 9 | 11 | 15 | 17 |
| Profit before tax | 25 | 43 | 69 | 86 | 175 | 183 | 228 | 250 |
| Tax % | 27.0% | 22.0% | 27.0% | 28.0% | 24.0% | 24.0% | 24.0% | — |
| Net Profit + | 18 | 33 | 50 | 62 | 133 | 139 | 174 | 189 |
| EPS in Rs | 2 | 4 | 6 | 7 | 16 | 14 | 15 | 17 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | 75 | 59 | 25 | 7 | 9 | 28 | 27 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Reserves | 80 | 113 | 162 | 222 | 355 | 481 | 872 | 946 |
| Borrowings + | 20 | 31 | 84 | 83 | 78 | 140 | 150 | 189 |
| Other Liabilities + | 30 | 67 | 97 | 113 | 80 | 86 | 141 | 182 |
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | 1,329 |
| Fixed Assets + | 60 | 68 | 137 | 158 | 180 | 189 | 337 | 524 |
| CWIP | 8 | 24 | 8 | 26 | 45 | 88 | 185 | 54 |
| Investments | 6 | 19 | 0 | 3 | 0 | 0 | 0 | 0 |
| Other Assets + | 57 | 102 | 199 | 232 | 289 | 439 | 652 | 751 |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | 1,329 |
| Equity Capital | 1 | 1 | 1 | 1 | 1 | 10 | 11 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 10 | 35 | -3 | 48 | 66 | 49 | 70 |
| Cash from Investing Activity + | -22 | -40 | -38 | -50 | -49 | -79 | -327 |
| Cash from Financing Activity + | 12 | 13 | 51 | -10 | -13 | 53 | 247 |
| Net Cash Flow | 0 | 8 | 10 | -11 | 4 | 23 | -10 |
| Free Cash Flow | 1 | 24 | -77 | 1 | 13 | -15 | -49 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 62 | 104 | 22 | 78 | 60 | 47 | 56 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|
| Public | 4.57% | 4.18% | 6.39% | 6.87% |
| Promoters | 76.16% | 76.16% | 76.16% | 76.16% |
| FII | 1.67% | 1.55% | 1.81% | 2.93% |
| DII | 17.59% | 18.11% | 15.64% | 14.06% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Sudeep Pharma Limited (this stock) | 13,545 | 71.9 | 14.14 | 25.2% |
| Marksans Pharma Limited | 13,347 | 23.8 | 4.0 | 15.2% |
| Corona Remedies Limited | 14,010 | 63.6 | 17.34 | 29.5% |
| Rainbow Childrens Med Ltd | 12,607 | 43.0 | 7.34 | 16.7% |
| Vijaya Diagnostic Cen Ltd | 14,524 | 71.3 | 13.69 | 18.9% |
| Jubilant Pharmova Ltd | 14,883 | 50.4 | 2.08 | 6.53% |
| Concord Biotech Limited | 12,146 | 42.6 | 5.86 | 12.9% |
Which Mutual Funds Hold Sudeep Pharma Limited?
Frequently Asked Questions about Sudeep Pharma Limited
Sudeep Pharma Limited (SUDEEPPHRM) closed at ₹1,212.1 on NSE on 19 November 2026, up 9.9 (0.82%) from the previous close.
Sudeep Pharma Limited trades on the NSE (National Stock Exchange of India) under the symbol SUDEEPPHRM.
Sudeep Pharma Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 71.9.
Sudeep Pharma Limited has a dividend yield of 0.13%.
Sudeep Pharma Limited's 52-week high is ₹1,378.0 and its 52-week low is ₹524.0.
Sudeep Pharma Limited has a market capitalisation of ₹13,545 crore.
Sudeep Pharma Limited has a TopFund Quality Score of 65/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Sudeep Pharma Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.